liraglutide Saxenda
Selected indexed studies
- Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis. (Mol Med, 2023) [PMID:37770820]
- Liraglutide (Saxenda) for Weight Loss. (Am Fam Physician, 2016) [PMID:27419334]
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. (J Clin Invest, 2014) [PMID:25202980]
_Worker-drafted node — pending editorial review._
Connections
liraglutide Saxenda is a side effect of
Sources
- Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis. (2023) pubmed
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. (2014) pubmed
- Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway. (2024) pubmed
- Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). (2020) pubmed
- Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. (2016) pubmed
- Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis. (2022) pubmed
- Liraglutide attenuates angiotensin II-induced aortic dissection and aortic aneurysm via inhibiting M1 macrophage polarization in APOE (-/-) mice. (2024) pubmed
- Liraglutide (Saxenda) for Weight Loss. (2016) pubmed
- Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial. (2016) pubmed
- Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes. (2024) pubmed